The biological age and longevity diagnostics market size has grown rapidly in recent years. It will grow from $2.9 billion in 2025 to $3.31 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to rising adoption of genomic sequencing in clinical research, increasing focus on preventive healthcare and early disease detection, growth in biomarker based diagnostic testing adoption, expansion of biotechnology research in aging studies, increasing healthcare digitization and electronic health records integration.
The biological age and longevity diagnostics market size is expected to see rapid growth in the next few years. It will grow to $5.58 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to expansion of ai driven precision medicine platforms, rising demand for personalized healthspan extension solutions, increasing integration of multi omics data analytics in diagnostics, growth of direct to consumer longevity testing services, advancement in real time biosensor and wearable diagnostics technologies. Major trends in the forecast period include increasing adoption of multi-omics integration for more accurate biological age prediction and healthspan assessment, rising use of ai-driven longevity models to correlate biomarkers with disease risk and aging trajectories, growing demand for early disease prediction through epigenetic and molecular aging signatures, expansion of personalized anti-aging intervention plans based on biological age diagnostics, increasing use of microbiome and metabolic profiling for holistic aging analysis and health optimization.
The increasing adoption of personalized medicine is expected to propel the growth of the biological age and longevity diagnostics market going forward. Personalized medicine refers to a medical approach that utilizes an individual's genetic, molecular, and clinical information to customize disease prevention, diagnosis, and treatment strategies for improved patient outcomes. The increasing adoption of personalized medicine is primarily driven by advancements in genomics and molecular diagnostics, which enable healthcare providers to analyze individual genetic profiles and disease biomarkers to deliver more precise and effective treatments. Biological age and longevity diagnostics support personalized medicine by providing individualized insights into biological aging processes through molecular, genetic, and biomarker-based assessments, enabling clinicians to tailor prevention, treatment, and lifestyle interventions more precisely than traditional age-based approaches. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, compared to six in 2022. The personalized treatments approved in 2023 also included seven cancer drugs and three therapies for other diseases and conditions. Therefore, the increasing adoption of personalized medicine is driving the growth of the biological age and longevity diagnostics market.
Key companies operating in the biological age and longevity diagnostics market are focusing on developing innovative solutions, such as multi-omics-based longevity assessment platforms, to enable more accurate measurement of biological age and deliver personalized, data-driven preventive healthcare insights. Multi-omics-based longevity assessment platforms integrate genomic, epigenomic, proteomic, metabolomic, and clinical biomarker data to estimate an individual’s biological age, which reflects physiological condition more accurately than chronological age. For example, in April 2026, Thrive Global, a US-based precision healthcare company, launched the Elite Longevity Assessment, a multi-omics-based longevity assessment platform to evaluate biological age using a combination of advanced biomarker panels, metabolic profiling, and lifestyle data integration. It leverages AI-powered analytics to generate individualized aging scores and healthspan forecasts, helping clinicians identify early signs of accelerated aging and underlying health risks. The assessment further provides personalized intervention recommendations, including nutrition, supplementation, and lifestyle optimization strategies to improve longevity outcomes and preventive care planning. The solution enhances traditional health checkups by shifting focus from disease detection to long-term health optimization and precision aging management.
In April 2026, Infinite Epigenetics, a US-based biotechnology company, acquired Tally Health for an undisclosed amount. Through this acquisition, Infinite Epigenetics aims to strengthen its position in the biological age and longevity diagnostics market by combining advanced epigenetic diagnostic capabilities with consumer-focused longevity testing and personalized intervention services to create a vertically integrated healthspan platform. Tally Health LLC is a US-based biotechnology company that provides at-home biological age testing, epigenetic analysis, personalized longevity recommendations, and healthy aging solutions.
Major companies operating in the biological age and longevity diagnostics market are Altos Labs; Infinite Epigenetics; TruDiagnostic; Viome Life Sciences Inc.; Function Health; Elysium Health Inc.; InsideTracker Inc.; Segterra Inc.; Human Longevity Inc.; FOXO Technologies Inc.; GlycanAge Ltd.; Gero PTE. Ltd.; Decode Age Technologies Pvt. Ltd.; MyDNAge Inc.; Generation Lab; SiPhox Inc; Neko Health; Circulate Health; EpiMedTech Global.
North America was the largest region in the biological age and longevity diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biological age and longevity diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biological age and longevity diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biological age and longevity diagnostics market consists of revenues earned by entities by providing services such as blood biomarker analysis, multi-omics profiling, and longevity health consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The biological age and longevity diagnostics market also includes sales of biological age testing kits, epigenetic and genetic testing products, biomarker analysis panels, wearable health monitoring devices, and biosensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The biological age and longevity diagnostics market research report is one of a series of new reports that provides biological age and longevity diagnostics market statistics, including biological age and longevity diagnostics industry global market size, regional shares, competitors with a biological age and longevity diagnostics market share, detailed biological age and longevity diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the biological age and longevity diagnostics industry. This biological age and longevity diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The biological age and longevity diagnostics market size is expected to see rapid growth in the next few years. It will grow to $5.58 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to expansion of ai driven precision medicine platforms, rising demand for personalized healthspan extension solutions, increasing integration of multi omics data analytics in diagnostics, growth of direct to consumer longevity testing services, advancement in real time biosensor and wearable diagnostics technologies. Major trends in the forecast period include increasing adoption of multi-omics integration for more accurate biological age prediction and healthspan assessment, rising use of ai-driven longevity models to correlate biomarkers with disease risk and aging trajectories, growing demand for early disease prediction through epigenetic and molecular aging signatures, expansion of personalized anti-aging intervention plans based on biological age diagnostics, increasing use of microbiome and metabolic profiling for holistic aging analysis and health optimization.
The increasing adoption of personalized medicine is expected to propel the growth of the biological age and longevity diagnostics market going forward. Personalized medicine refers to a medical approach that utilizes an individual's genetic, molecular, and clinical information to customize disease prevention, diagnosis, and treatment strategies for improved patient outcomes. The increasing adoption of personalized medicine is primarily driven by advancements in genomics and molecular diagnostics, which enable healthcare providers to analyze individual genetic profiles and disease biomarkers to deliver more precise and effective treatments. Biological age and longevity diagnostics support personalized medicine by providing individualized insights into biological aging processes through molecular, genetic, and biomarker-based assessments, enabling clinicians to tailor prevention, treatment, and lifestyle interventions more precisely than traditional age-based approaches. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, compared to six in 2022. The personalized treatments approved in 2023 also included seven cancer drugs and three therapies for other diseases and conditions. Therefore, the increasing adoption of personalized medicine is driving the growth of the biological age and longevity diagnostics market.
Key companies operating in the biological age and longevity diagnostics market are focusing on developing innovative solutions, such as multi-omics-based longevity assessment platforms, to enable more accurate measurement of biological age and deliver personalized, data-driven preventive healthcare insights. Multi-omics-based longevity assessment platforms integrate genomic, epigenomic, proteomic, metabolomic, and clinical biomarker data to estimate an individual’s biological age, which reflects physiological condition more accurately than chronological age. For example, in April 2026, Thrive Global, a US-based precision healthcare company, launched the Elite Longevity Assessment, a multi-omics-based longevity assessment platform to evaluate biological age using a combination of advanced biomarker panels, metabolic profiling, and lifestyle data integration. It leverages AI-powered analytics to generate individualized aging scores and healthspan forecasts, helping clinicians identify early signs of accelerated aging and underlying health risks. The assessment further provides personalized intervention recommendations, including nutrition, supplementation, and lifestyle optimization strategies to improve longevity outcomes and preventive care planning. The solution enhances traditional health checkups by shifting focus from disease detection to long-term health optimization and precision aging management.
In April 2026, Infinite Epigenetics, a US-based biotechnology company, acquired Tally Health for an undisclosed amount. Through this acquisition, Infinite Epigenetics aims to strengthen its position in the biological age and longevity diagnostics market by combining advanced epigenetic diagnostic capabilities with consumer-focused longevity testing and personalized intervention services to create a vertically integrated healthspan platform. Tally Health LLC is a US-based biotechnology company that provides at-home biological age testing, epigenetic analysis, personalized longevity recommendations, and healthy aging solutions.
Major companies operating in the biological age and longevity diagnostics market are Altos Labs; Infinite Epigenetics; TruDiagnostic; Viome Life Sciences Inc.; Function Health; Elysium Health Inc.; InsideTracker Inc.; Segterra Inc.; Human Longevity Inc.; FOXO Technologies Inc.; GlycanAge Ltd.; Gero PTE. Ltd.; Decode Age Technologies Pvt. Ltd.; MyDNAge Inc.; Generation Lab; SiPhox Inc; Neko Health; Circulate Health; EpiMedTech Global.
North America was the largest region in the biological age and longevity diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biological age and longevity diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biological age and longevity diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biological age and longevity diagnostics market consists of revenues earned by entities by providing services such as blood biomarker analysis, multi-omics profiling, and longevity health consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The biological age and longevity diagnostics market also includes sales of biological age testing kits, epigenetic and genetic testing products, biomarker analysis panels, wearable health monitoring devices, and biosensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The biological age and longevity diagnostics market research report is one of a series of new reports that provides biological age and longevity diagnostics market statistics, including biological age and longevity diagnostics industry global market size, regional shares, competitors with a biological age and longevity diagnostics market share, detailed biological age and longevity diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the biological age and longevity diagnostics industry. This biological age and longevity diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Biological Age And Longevity Diagnostics Market Characteristics
3. Biological Age And Longevity Diagnostics Market Supply Chain Analysis
4. Global Biological Age And Longevity Diagnostics Market Trends And Strategies
5. Biological Age And Longevity Diagnostics Market Analysis Of End Use Industries
7. Global Biological Age And Longevity Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Biological Age And Longevity Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Biological Age And Longevity Diagnostics Market Segmentation
10. Biological Age And Longevity Diagnostics Market Regional And Country Analysis
11. Asia-Pacific Biological Age And Longevity Diagnostics Market
12. China Biological Age And Longevity Diagnostics Market
13. India Biological Age And Longevity Diagnostics Market
14. Japan Biological Age And Longevity Diagnostics Market
15. Australia Biological Age And Longevity Diagnostics Market
16. Indonesia Biological Age And Longevity Diagnostics Market
17. South Korea Biological Age And Longevity Diagnostics Market
18. Taiwan Biological Age And Longevity Diagnostics Market
19. South East Asia Biological Age And Longevity Diagnostics Market
20. Western Europe Biological Age And Longevity Diagnostics Market
21. UK Biological Age And Longevity Diagnostics Market
22. Germany Biological Age And Longevity Diagnostics Market
23. France Biological Age And Longevity Diagnostics Market
24. Italy Biological Age And Longevity Diagnostics Market
25. Spain Biological Age And Longevity Diagnostics Market
26. Eastern Europe Biological Age And Longevity Diagnostics Market
27. Russia Biological Age And Longevity Diagnostics Market
28. North America Biological Age And Longevity Diagnostics Market
29. USA Biological Age And Longevity Diagnostics Market
30. Canada Biological Age And Longevity Diagnostics Market
31. South America Biological Age And Longevity Diagnostics Market
32. Brazil Biological Age And Longevity Diagnostics Market
33. Middle East Biological Age And Longevity Diagnostics Market
34. Africa Biological Age And Longevity Diagnostics Market
36. Biological Age And Longevity Diagnostics Market Competitive Landscape And Company Profiles
37. Biological Age And Longevity Diagnostics Market Other Major And Innovative Companies
41. Biological Age And Longevity Diagnostics Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Biological Age And Longevity Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses biological age and longevity diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biological age and longevity diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biological age and longevity diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: Epigenetic Age Testing; Telomere Length Testing; Multi Omics Diagnostics; Proteomic Aging Tests; Microbiome Based Longevity Diagnostics; Cellular Senescence Biomarker Tests; Organ Age Assessment Tests2) By Sample Type: Blood Samples; Saliva Samples; Urine Samples; Tissue Samples; Buccal Swab Samples; Hair Samples
3) By Application Type: Preventive Healthcare; Personalized Medicine; Chronic Disease Risk Assessment; Wellness And Fitness Monitoring; Anti Aging Research
4) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Longevity Clinics; Academic Institutions; Direct To Consumer Users; Pharmaceutical And Biotechnology Companies
Subsegments:
1) By Epigenetic Age Testing: Deoxyribonucleic Acid Methylation Testing; Histone Modification Analysis; Chromatin Accessibility Profiling; Epigenetic Clock Assessment; Age Prediction Biomarker Testing2) By Telomere Length Testing: Quantitative Polymerase Chain Reaction Testing; Flow Cytometry And Fluorescence In Situ Hybridization; Southern Blot Analysis; Single Telomere Length Analysis; Telomerase Activity Testing
3) By Multi Omics Diagnostics: Genomics Analysis; Transcriptomics Analysis; Proteomics Analysis; Metabolomics Analysis; Lipidomics Analysis
4) By Proteomic Aging Tests: Plasma Protein Biomarker Testing; Inflammatory Protein Analysis; Cytokine Profiling; Enzyme Activity Analysis; Growth Factor Biomarker Testing
5) By Microbiome Based Longevity Diagnostics: Gut Microbiome Sequencing; Microbial Diversity Analysis; Functional Microbiome Profiling; Stool Biomarker Testing; Microbial Metabolite Analysis
6) By Cellular Senescence Biomarker Tests: Senescence Associated Beta Galactosidase Testing; Cellular Stress Marker Analysis; Cell Cycle Arrest Biomarker Testing; Senescence Secretory Phenotype Profiling; Deoxyribonucleic Acid Damage Response Testing
7) By Organ Age Assessment Tests: Cardiovascular Age Assessment; Brain Age Assessment; Liver Age Assessment; Kidney Age Assessment; Lung Age Assessment
Companies Mentioned: Altos Labs; Infinite Epigenetics; TruDiagnostic; Viome Life Sciences Inc.; Function Health; Elysium Health Inc.; InsideTracker Inc.; Segterra Inc.; Human Longevity Inc.; FOXO Technologies Inc.; GlycanAge Ltd.; Gero PTE. Ltd.; Decode Age Technologies Pvt. Ltd.; MyDNAge Inc.; Generation Lab; SiPhox Inc; Neko Health; Circulate Health; EpiMedTech Global
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Altos Labs
- Infinite Epigenetics
- TruDiagnostic
- Viome Life Sciences Inc.
- Function Health
- Elysium Health Inc.
- InsideTracker Inc.
- Segterra Inc.
- Human Longevity Inc.
- FOXO Technologies Inc.
- GlycanAge Ltd.
- Gero PTE. Ltd.
- Decode Age Technologies Pvt. Ltd.
- MyDNAge Inc.
- Generation Lab
- SiPhox Inc
- Neko Health
- Circulate Health
- EpiMedTech Global
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | August 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.31 Billion |
| Forecasted Market Value ( USD | $ 5.58 Billion |
| Compound Annual Growth Rate | 13.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
